Get to know our clinical trials
Clinical trial to evaluate the efficacy, safety and tolerability of ianalumab in combination with standard therapy in participants with active lupus nephritis (SIRIUS-LN)
THE PURPOSE OF THIS STUDY IS TO DETERMINE HOW IANALUMAB WORKS IN PARTICIPANTS WITH NL. - TO DETERMINE IF IANALUMAB CAN HELP TREAT NL. - TO DETERMINE IF IT IS SAFE FOR PARTICIPANTS WITH NL TO TAKE IANALUMAB. - TO COMPARE DIFFERENT IANALUMAB REGIMENS AND SEE WHICH WORKS BEST - TO SEE IF GIVING IANALUMAB WITH STANDARD TREATMENT (SOC) IS BETTER THAN USING SOC ALONE WITH NO ACTIVE TREATMENT (PLACEBO). A PLACEBO IS A DRUG WITH NO ACTIVE INGREDIENTS INSIDE.
Technical Summary
- PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF IANALUMAB IN COMBINATION WITH STANDARD THERAPY IN PARTICIPANTS WITH ACTIVE LUPUS NEPHRITIS (SIRIUS-LN).
- Code EudraCT: 2020-005830-14
- Protocol number: CVAY736K12301
- Promoter: Novartis Farmaceutica
- Molecule/Drug: ianalumab
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.